RU2017106945A - Пептиды, применимые для лечения злокачественной опухоли - Google Patents

Пептиды, применимые для лечения злокачественной опухоли Download PDF

Info

Publication number
RU2017106945A
RU2017106945A RU2017106945A RU2017106945A RU2017106945A RU 2017106945 A RU2017106945 A RU 2017106945A RU 2017106945 A RU2017106945 A RU 2017106945A RU 2017106945 A RU2017106945 A RU 2017106945A RU 2017106945 A RU2017106945 A RU 2017106945A
Authority
RU
Russia
Prior art keywords
compound
pro
malignant tumor
arg
hca
Prior art date
Application number
RU2017106945A
Other languages
English (en)
Russian (ru)
Other versions
RU2017106945A3 (enExample
Inventor
Хильмар М ВАРЕНИУС
Original Assignee
Хильмар М ВАРЕНИУС
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Хильмар М ВАРЕНИУС filed Critical Хильмар М ВАРЕНИУС
Publication of RU2017106945A publication Critical patent/RU2017106945A/ru
Publication of RU2017106945A3 publication Critical patent/RU2017106945A3/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/64—Cyclic peptides containing only normal peptide links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7004—Monosaccharides having only carbon, hydrogen and oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/1048—Glycosyltransferases (2.4)
    • C12N9/1077—Pentosyltransferases (2.4.2)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y204/00—Glycosyltransferases (2.4)
    • C12Y204/02—Pentosyltransferases (2.4.2)
    • C12Y204/0203—NAD+ ADP-ribosyltransferase (2.4.2.30), i.e. tankyrase or poly(ADP-ribose) polymerase
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56966—Animal cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/10—Fusion polypeptide containing a localisation/targetting motif containing a tag for extracellular membrane crossing, e.g. TAT or VP22

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Cell Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
RU2017106945A 2014-08-06 2015-08-05 Пептиды, применимые для лечения злокачественной опухоли RU2017106945A (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB1413942.2 2014-08-06
GB1413942.2A GB2530479A (en) 2014-08-06 2014-08-06 Peptides useful for treating cancer
PCT/EP2015/068056 WO2016020437A1 (en) 2014-08-06 2015-08-05 Peptides useful for treating cancer

Publications (2)

Publication Number Publication Date
RU2017106945A true RU2017106945A (ru) 2018-09-06
RU2017106945A3 RU2017106945A3 (enExample) 2019-03-28

Family

ID=51587828

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2017106945A RU2017106945A (ru) 2014-08-06 2015-08-05 Пептиды, применимые для лечения злокачественной опухоли

Country Status (9)

Country Link
US (1) US20170313746A1 (enExample)
EP (1) EP3177716A1 (enExample)
JP (1) JP2017529386A (enExample)
CN (1) CN107406485A (enExample)
AU (1) AU2015299032A1 (enExample)
CA (1) CA2960070A1 (enExample)
GB (1) GB2530479A (enExample)
RU (1) RU2017106945A (enExample)
WO (1) WO2016020437A1 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017066454A2 (en) 2015-10-14 2017-04-20 X-Therma, Inc. Compositions and methods for reducing ice crystal formation
GB201602409D0 (en) * 2016-02-10 2016-03-23 Warenius Hilmar M Compositions and uses thereof
GB2582571B (en) 2019-03-25 2024-02-28 Syntherix Ltd Peptides and use thereof
CN113109418B (zh) * 2021-04-21 2022-09-09 苏州大学 一种己糖激酶2抑制剂的筛选方法和小分子化合物在制备抗肿瘤药物中的应用
GB2628421A (en) 2023-03-24 2024-09-25 Syntherix Ltd Peptides and uses thereof

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2002236569A1 (en) * 2000-12-04 2002-06-18 Sloan-Kettering Institute For Cancer Research Treatment of cancer by reduction of intracellular energy and pyrimidines
AU2002316419A1 (en) * 2001-07-05 2003-01-21 Yale University Improvement of viral uptake into cells and tissues
US7439031B2 (en) * 2003-12-15 2008-10-21 The Trustees Of The University Of Pennsylvania Method of identifying compounds that induce cell death by necrosis
GB0804496D0 (en) * 2008-03-11 2008-04-16 Theryte Ltd Treating cancer
EP2867662B1 (en) * 2012-06-27 2021-01-06 Siscapa Assay Technologies, Inc. Multipurpose mass spectrometric assay panels for peptides
EP3456734B1 (en) * 2012-10-04 2022-01-05 Research Development Foundation Serine protease molecules and therapies
WO2014053879A1 (en) * 2012-10-04 2014-04-10 Centre National De La Recherche Scientifique Cell penetrating peptides for intracellular delivery of molecules

Also Published As

Publication number Publication date
GB2530479A (en) 2016-03-30
WO2016020437A1 (en) 2016-02-11
US20170313746A1 (en) 2017-11-02
CN107406485A (zh) 2017-11-28
AU2015299032A1 (en) 2017-03-23
JP2017529386A (ja) 2017-10-05
GB201413942D0 (en) 2014-09-17
EP3177716A1 (en) 2017-06-14
RU2017106945A3 (enExample) 2019-03-28
CA2960070A1 (en) 2016-02-11

Similar Documents

Publication Publication Date Title
US20230212549A1 (en) Compounds comprising a fibroblast activation protein ligand and use thereof
US20240115745A1 (en) Compounds comprising a fibroblast activation protein ligand and use thereof
AU2026202638A1 (en) Compounds comprising a fibroblast activation protein ligand and use thereof
WO2022017375A1 (zh) 一种FAP-α特异性肿瘤诊断SPECT显像剂
Miao et al. In vivo evaluation of 188Re‐labeled alpha‐melanocyte stimulating hormone peptide analogs for melanoma therapy
IL320543A (en) Compounds comprising a fibroblast activation protein ligand and use thereof
JP7667765B2 (ja) がんイメージング及びがん放射線治療のための組成物及び方法
CN111065646A (zh) 放射性药物
EP3763726A1 (en) Compounds comprising a fibroblast activation protein ligand and use thereof
JP2022507296A (ja) ガストリン放出ペプチド受容体（ｇｒｐｒ）のインビボイメージングおよびｇｒｐｒ関連障害の治療のための放射性標識ボンベシン由来化合物
CN114364690A (zh) 用于诊断和治疗的新型放射性标记的cxcr4靶向化合物
WO2023133645A1 (en) Radiolabeled compounds for imaging of fibroblast activation protein (fap) and treatment of fap-related disorders
AU2012361902B2 (en) Integrin blocker polypeptide and use thereof
EP4692105A1 (en) Cyclic polypeptide compound and use thereof
JPH04500805A (ja) 標的剤
Sano et al. A radiogallium–DOTA-based bivalent peptidic ligand targeting a chemokine receptor, CXCR4, for tumor imaging
RU2018131821A (ru) Композиции и их применения
Chen et al. A Novel 68Ga‐Labeled 2‐Azabicyclo [3.1. 0] Hexane‐3‐Carbonitrile‐Based Fibroblast Activation Protein‐Targeted Tracer for Cancer Imaging With Positron Emission Tomography
US11077217B2 (en) Radioactive labeling method for neuropeptide Y derivative compound and medicine for multi-type breast cancer therapy thereof
WO2025059775A1 (en) Radiolabeled melanocortin 1 receptor-specific alpha-melanocyte-stimulating hormone analogues for imaging or therapy
WO2024046469A1 (zh) 环肽及其制备方法、包括其的复合物、及其用途
Jiang et al. NOVEL, CYSTEINE-MODIFIED CHELATION STRATEGY FOR THE
Xavier Tricarbonyl complexes for the design of specific radiopharmaceuticals for endogenous gene expression and membrane receptor imaging
HK40029075A (en) Radioactive drug
Leung 68Ga-CHX-A”-Rhenium-cyclized-[Cys3, 4, 10, D-Phe7, Arg11] α-MSH3-13

Legal Events

Date Code Title Description
FA92 Acknowledgement of application withdrawn (lack of supplementary materials submitted)

Effective date: 20210219